Browsing by Author "Cassidy, J."
Now showing items 1-2 of 2
-
Article
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group
Dirix, L. Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; Huinink, W. W. Ten Bokkel; Pavlidis, Nicholas; Sorio, R.; Gamucci, T.; Wolff, I.; Velde, A. Te; Lan, J.; Verweij, J. (1996)In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, ...
-
Article
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9
Schellens, J. H. M.; Dombernowsky, P.; Cassidy, J.; Epelbaum, R.; Dirix, L.; Cox, E. H.; Wanders, J.; Calabresi, F.; Paridaens, R.; Monfardini, S.; Wolff, J.; Loos, W. J.; Verweij, J.; Pavlidis, Nicholas; Hanauske, A. R. (2001)Population pharmacokinetic-dynamic analysis was prospectively integrated in the clinical phase II programme of EO9 to determine the population pharmacokinetic profile in a larger population of patients, to estimate individual ...